

Medicines for Children (2005 HTA Programme)

The first HTA themed call covered the broad area of medicines for children, in support of the newly formed Medicines for Children Research Network (MCRN). This was set up to target the development of safe and effective medicines for the treatment of youngsters aged newborn to 18 years.

Full research proposals from 16 teams (shortlisted from 52) were considered by the HTA Medicines for Children Assessment Board in May 2006, and a portfolio of seven projects were commissioned.

Funding Outcomes		
Research Programme	Application Title	Lead Applicant
HTA	Cryotherapy versus salicylic acid for the treatment of verrucae: A randomised controlled trial.	Mrs Elizabeth Cockayne, University of York
HTA	Control of Hyperglycaemia In Paediatric intensive care trial (The CHIP trial)	Dr Duncan Macrae, Royal Brompton Hospital
HTA	Death in the context of a randomised controlled trial: a methodological study of policy	Professor Diana Elbourne, London

Funding Outcomes

Research Programme	Application Title	Lead Applicant
	and practice in neonatal and paediatric intensive care trials	School of Hygiene & Tropical Medicine
HTA	Processes in recruitment to randomised controlled trials (RCTs) of medicines for children	Dr Bridget Young, University of Liverpool
HTA	Early administration to preterm infants of Bifidobacterium breve strain BBG to prevent infection and necrotising enterocolitis	Professor Kate Costeloe, Queen Mary, University of London
HTA	How should asthma in school-aged children be managed when not controlled with low-dose inhaled corticosteroids (ICS)?	Professor Warren Lenney, University Hospital of North Staffordshire
HTA	MAGnesium NEbuliser Trial (MAGNET)	Dr Colin Powell, Children's Hospital for Wales

Funding Outcomes

Research Programme	Application Title	Lead Applicant
HTA	SLEEPS: Safety profile, Efficacy and Equivalence in Paediatric intensive care Sedation: A Comparison of Clonidine and Midazolam	Professor Andrew Wolf, Bristol Royal Hospital for Children